Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.
Market Cap | 1.003 Billion | Shares Outstanding | 67.378 Million | Avg 30-day Volume | 1.95 Million |
P/E Ratio | 695.586 | Dividend Yield | 0.0 | EPS | -0.92 |
Price to Revenue | 4.3406 | Debt to Equity | 0.0 | EBITDA | -17.504 Million |
Price to Book Value | 3.0523 | Operating Margin | -2.6256000000000004 | Enterprise Value | 922.051 Million |
Current Ratio | 9.516 | EPS Growth | 1.003 | Quick Ratio | 8.427 |
1 Yr BETA | 1.2426 | 52-week High/Low | 41.93 / 11.82 | Profit Margin | 0.624 |
Operating Cash Flow Growth | 67.599 | Free Cash Flow to Firm (FCFF) TTM | -84.41 Million | Free Cash Flow to Equity (FCFE) TTM | -3.995 Million |
Altman Z-Score | 16.5379 |
Please sign in first
none
none
63.7 Thousand total shares from 1 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BEDROSIAN CAMILLE L CHIEF MEDICAL OFFICER |
|
0 | 2023-11-27 | 2 |
COHEN JOSHUA B CO-CHIEF EXECUTIVE OFFICER |
|
2,906,311 | 2023-11-16 | 3 |
FRATES JAMES M CHIEF FINANCIAL OFFICER |
|
125,823 | 2023-10-31 | 7 |
|
4,997,302 | 2023-08-15 | 10 | |
MAZZARIELLO GINA CHIEF LEGAL OFFICER |
|
49,083 | 2023-08-15 | 4 |
OLINGER MARGARET CHIEF COMMERCIAL OFFICER |
|
251,108 | 2023-07-12 | 4 |
|
0 | 2023-06-08 | 3 | |
|
0 | 2023-06-08 | 1 | |
|
0 | 2023-06-08 | 1 | |
|
0 | 2023-06-08 | 3 | |
YERAMIAN PATRICK D CHIEF MEDICAL OFFICER |
|
208,417 | 2023-05-15 | 5 |
KLEE JUSTIN B. CO-CHIEF EXECUTIVE OFFICER |
|
2,842,617 | 2023-03-16 | 2 |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC VIKING GLOBAL OPPORTUNITIES GP LLC |
|
5,770,536 | 2022-09-08 | 0 |
|
5,895,280 | 2022-07-06 | 0 | |
|
19,000 | 2022-06-09 | 0 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC VIKING GLOBAL OPPORTUNITIES GP LLC |
|
7,170,536 | 2022-01-11 | 0 |
|
2,300,000 | 2022-01-11 | 0 | |
|
10,678,808 | 2022-01-06 | 10 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-29 16:49:00 -0500 | 2023-11-27 | A | 58,333 | a | 58,333 | direct | 0.4237 | 0.4237 | 2 | 0.0 | 1 | |||||
2023-11-29 16:49:00 -0500 | 2023-11-27 | A | 162,500 | a | 162,500 | direct | ||||||||||
COHEN JOSHUA B - Director - Officer CO-CHIEF EXECUTIVE OFFICER |
2023-11-20 20:20:39 -0500 | 2023-11-16 | M | 63,694 | $1.57 | a | 2,906,311 | direct | 0.5538 | 7.4367 | 7.4367 | 6 | 0.0 | 1 | ||
COHEN JOSHUA B - Director - Officer CO-CHIEF EXECUTIVE OFFICER |
2023-11-20 20:20:39 -0500 | 2023-11-16 | M | 63,694 | d | 36,306 | direct | |||||||||
2023-11-02 15:33:04 -0400 | 2023-10-31 | G | 11,072 | a | 11,072 | indirect | -2.6044 | -32.2843 | 0.0 | 1 | -33.478 | 5 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 20:15:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 19:45:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 19:15:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 18:45:03 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 18:15:03 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 17:45:03 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 17:15:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 16:45:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 16:15:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 15:45:03 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 15:15:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 14:45:04 UTC | 4.3784 | 0.9416 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 14:15:04 UTC | 4.3784 | 0.9416 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 13:45:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-06 13:15:04 UTC | 4.4301 | 0.8899 | 1900000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-05 22:15:04 UTC | 4.4301 | 0.8899 | 1800000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-05 21:45:04 UTC | 4.4301 | 0.8899 | 1800000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-05 21:15:04 UTC | 4.4301 | 0.8899 | 1800000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-05 20:45:04 UTC | 4.4301 | 0.8899 | 1800000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-12-05 20:15:04 UTC | 4.4301 | 0.8899 | 1800000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | AMLX | -1086.0 shares, $-25466.7 | 2023-07-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | AMLX | -10500.0 shares, $-192255.0 | 2023-09-30 | N-PORT |
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | AMLX | -267.0 shares, $-4888.77 | 2023-09-30 | N-PORT |